The Company welcomes new development partnerships and collaborations with both industry and academia for its proprietary oral T-cell activation therapy platform and product candidates. VAXIMM works with leading academic institutions and pharmaceutical companies in its development activities.

The Company is seeking funding to advance its COVID-19 vaccine development project.

For more information, please contact us.
Please read the Terms of Use and Privacy Policy and confirm your acknowledgement by ticking the box:
Then you will be automatically forwarded to our e-mail form.